FDA PMA
FDA Class 2
30-Day Notice Accepted
🇺🇸 United States
Assay, Genotyping, Hepatitis C Virus
PMA: P120012
·
Supplement: S019
·
Decision Mar 5, 2021
Classifications
1
FEI Numbers
5
Registration Numbers
5
Basic Information
- Device Name
- Assay, Genotyping, Hepatitis C Virus
- Trade Name
- Abbott RealTime HCV Genotype II
- PMA Number
- P120012
- Supplement Number
- S019
- Device Class
- FDA Class 2
- Product Code
- OBF
- Generic Name
- Assay, genotyping, hepatitis c virus
- Regulation Number
- 866.3170
- Medical Specialty
- Microbiology
- Advisory Committee
- Microbiology
- Decision
- 30-Day Notice Accepted
- Decision Code
- OK30
- Decision Date
- March 5, 2021
- Date Received
- February 5, 2021
- Supplement Type
- 30-Day Notice
- Supplement Reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Expedited Review
- N
Advisory Committee Statement
Addition of alternative testing location for a device component.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| OBF | Assay, Genotyping, Hepatitis C Virus | FDA class 2 | Microbiology |